STOCK TITAN

[Form 4] Twist Bioscience Corporation Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Negative)
Form Type
4
Rhea-AI Filing Summary

Paula Green, Senior Vice President of Human Resources at Twist Bioscience Corporation (TWST), reported a sale of company stock on 08/21/2025. The Form 4 shows 619 shares were disposed of at a price of $25.964 per share as a sell-to-cover transaction to satisfy tax withholding on vested Restricted Stock Units. After the transaction the reporting person beneficially owned 125,729 shares, which the filing notes includes shares acquired under the company Employee Stock Purchase Plan that were exempt under Rule 16b-3. The form was signed by an attorney-in-fact on 08/25/2025.

Paula Green, Senior Vice President delle Risorse Umane di Twist Bioscience Corporation (TWST), ha comunicato la vendita di azioni della società il 21/08/2025. Il Modulo 4 indica che sono state cedute 619 azioni a $25,964 per azione in un'operazione di sell-to-cover per coprire le imposte dovute su Restricted Stock Units maturate. Dopo la transazione la dichiarante deteneva beneficiariamente 125.729 azioni, comprensive, come riportato nel deposito, delle azioni acquisite tramite il Piano di Acquisto Azionario per i dipendenti esentate ai sensi della Regola 16b-3. Il modulo è stato firmato da un procuratore il 25/08/2025.

Paula Green, Vicepresidenta Senior de Recursos Humanos de Twist Bioscience Corporation (TWST), informó la venta de acciones de la compañía el 21/08/2025. El Formulario 4 muestra que se dispusieron 619 acciones a $25,964 por acción en una operación de sell-to-cover para cubrir retenciones fiscales sobre Unidades de Acciones Restringidas devengadas. Tras la transacción, la informante poseía beneficiariamente 125.729 acciones, cifra que, según la presentación, incluye acciones adquiridas mediante el Plan de Compra de Acciones para Empleados exentas según la Norma 16b-3. El formulario fue firmado por un apoderado el 25/08/2025.

Paula Green, Twist Bioscience Corporation (TWST) 인사담당 수석부사장이 2025-08-21에 회사 주식을 매도했다고 보고했습니다. Form 4에 따르면, 619주가 주당 $25.964에 처분되었으며 이는 행사된 제한주식유닛(RSU)의 세금 원천징수를 충당하기 위한 sell-to-cover 거래였습니다. 거래 후 보고자는 125,729주를 실소유하고 있었으며, 제출서에는 이 중 직원 주식 매입 계획(ESPP)을 통해 취득한 주식이 규정 16b-3에 따라 면제 대상이라고 기재되어 있습니다. 해당 서류는 2025-08-25에 대리 서명되었습니다.

Paula Green, Senior Vice President des Ressources Humaines chez Twist Bioscience Corporation (TWST), a déclaré la vente d'actions de la société le 21/08/2025. Le formulaire 4 indique que 619 actions ont été cédées à 25,964 $ par action dans le cadre d'une opération de sell-to-cover destinée à couvrir les retenues fiscales sur des Restricted Stock Units acquises. Après la transaction, la déclarante détenait à titre bénéficiaire 125 729 actions, lesquelles incluent, selon le dépôt, des actions obtenues via le Plan d'Achat d'Actions Employés exemptées en vertu de la règle 16b-3. Le formulaire a été signé par un mandataire le 25/08/2025.

Paula Green, Senior Vice President Human Resources bei Twist Bioscience Corporation (TWST), meldete am 21.08.2025 den Verkauf von Unternehmensaktien. Im Formular 4 ist verzeichnet, dass 619 Aktien zu je $25,964 veräußert wurden – als sell-to-cover-Transaktion zur Begleichung der Steuerabzüge auf fällige Restricted Stock Units. Nach der Transaktion besaß die meldende Person wirtschaftlich 125.729 Aktien; die Einreichung weist darauf hin, dass hierin Aktien aus dem Employee Stock Purchase Plan enthalten sind, die gemäß Regel 16b-3 ausgenommen sind. Das Formular wurde am 25.08.2025 von einem Bevollmächtigten unterschrieben.

Positive
  • Sale identified as a sell-to-cover, indicating the disposition was to satisfy tax withholding on vested RSUs rather than a discretionary trade
  • Beneficial ownership remains substantial at 125,729 shares after the transaction
  • ESP P shares explicitly noted as exempt under Rule 16b-3, clarifying compliance with insider-trading rules
Negative
  • Reporting person disposed of 619 shares, which represents an insider sale disclosed publicly

Insights

TL;DR Routine sell-to-cover sale by an officer to satisfy tax withholding; not a discretionary market sale.

The transaction reported is a mandated sell-to-cover tied to RSU vesting rather than an open-market, discretionary sale. The number of shares sold (619) and the stated purpose reduce the likelihood this trade materially signals a change in the reporting person’s view of company prospects. The post-transaction beneficial ownership (125,729 shares) still reflects meaningful equity exposure, including ESPP shares acquired under exempt provisions.

TL;DR Disclosure is consistent with standard insider reporting and equity plan procedures.

The Form 4 clearly identifies the reporting person’s role (SVP HR), the non-discretionary nature of the sale, and the inclusion of ESPP shares in beneficial ownership. The filing was executed via attorney-in-fact and contains explanatory notes clarifying compliance with equity-plan withholding mechanics. This meets typical governance and SEC disclosure expectations for employee equity transactions.

Paula Green, Senior Vice President delle Risorse Umane di Twist Bioscience Corporation (TWST), ha comunicato la vendita di azioni della società il 21/08/2025. Il Modulo 4 indica che sono state cedute 619 azioni a $25,964 per azione in un'operazione di sell-to-cover per coprire le imposte dovute su Restricted Stock Units maturate. Dopo la transazione la dichiarante deteneva beneficiariamente 125.729 azioni, comprensive, come riportato nel deposito, delle azioni acquisite tramite il Piano di Acquisto Azionario per i dipendenti esentate ai sensi della Regola 16b-3. Il modulo è stato firmato da un procuratore il 25/08/2025.

Paula Green, Vicepresidenta Senior de Recursos Humanos de Twist Bioscience Corporation (TWST), informó la venta de acciones de la compañía el 21/08/2025. El Formulario 4 muestra que se dispusieron 619 acciones a $25,964 por acción en una operación de sell-to-cover para cubrir retenciones fiscales sobre Unidades de Acciones Restringidas devengadas. Tras la transacción, la informante poseía beneficiariamente 125.729 acciones, cifra que, según la presentación, incluye acciones adquiridas mediante el Plan de Compra de Acciones para Empleados exentas según la Norma 16b-3. El formulario fue firmado por un apoderado el 25/08/2025.

Paula Green, Twist Bioscience Corporation (TWST) 인사담당 수석부사장이 2025-08-21에 회사 주식을 매도했다고 보고했습니다. Form 4에 따르면, 619주가 주당 $25.964에 처분되었으며 이는 행사된 제한주식유닛(RSU)의 세금 원천징수를 충당하기 위한 sell-to-cover 거래였습니다. 거래 후 보고자는 125,729주를 실소유하고 있었으며, 제출서에는 이 중 직원 주식 매입 계획(ESPP)을 통해 취득한 주식이 규정 16b-3에 따라 면제 대상이라고 기재되어 있습니다. 해당 서류는 2025-08-25에 대리 서명되었습니다.

Paula Green, Senior Vice President des Ressources Humaines chez Twist Bioscience Corporation (TWST), a déclaré la vente d'actions de la société le 21/08/2025. Le formulaire 4 indique que 619 actions ont été cédées à 25,964 $ par action dans le cadre d'une opération de sell-to-cover destinée à couvrir les retenues fiscales sur des Restricted Stock Units acquises. Après la transaction, la déclarante détenait à titre bénéficiaire 125 729 actions, lesquelles incluent, selon le dépôt, des actions obtenues via le Plan d'Achat d'Actions Employés exemptées en vertu de la règle 16b-3. Le formulaire a été signé par un mandataire le 25/08/2025.

Paula Green, Senior Vice President Human Resources bei Twist Bioscience Corporation (TWST), meldete am 21.08.2025 den Verkauf von Unternehmensaktien. Im Formular 4 ist verzeichnet, dass 619 Aktien zu je $25,964 veräußert wurden – als sell-to-cover-Transaktion zur Begleichung der Steuerabzüge auf fällige Restricted Stock Units. Nach der Transaktion besaß die meldende Person wirtschaftlich 125.729 Aktien; die Einreichung weist darauf hin, dass hierin Aktien aus dem Employee Stock Purchase Plan enthalten sind, die gemäß Regel 16b-3 ausgenommen sind. Das Formular wurde am 25.08.2025 von einem Bevollmächtigten unterschrieben.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Green Paula

(Last) (First) (Middle)
C/O TWIST BIOSCIENCE CORPORATION
681 GATEWAY BLVD.

(Street)
SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Twist Bioscience Corp [ TWST ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
SVP of Human Resources
3. Date of Earliest Transaction (Month/Day/Year)
08/21/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 08/21/2025 S 619(1) D $25.964 125,729(2) D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.
2. Includes shares that were acquired under the Issuer's Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c).
Remarks:
/s/ Kendra Fox, as Attorney-in-Fact for Paula Green 08/25/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Paula Green (TWST) report on the Form 4?

The Form 4 reports a sale of 619 shares on 08/21/2025 at $25.964 per share, executed as a sell-to-cover to satisfy tax withholding on vested RSUs.

How many TWST shares does the reporting person own after the transaction?

Following the reported transaction the reporting person beneficially owned 125,729 shares, which includes shares from the Employee Stock Purchase Plan.

Was the sale by Paula Green discretionary or mandated?

The filing states the sale was a mandated sell-to-cover required by the issuer's equity incentive plan to satisfy tax withholding obligations, not a discretionary trade.

What price were the shares sold at in the Form 4?

The reported sale price was $25.964 per share.

Who signed the Form 4 and when?

The Form 4 was signed by an attorney-in-fact, /s/ Kendra Fox, on 08/25/2025.
Twist Bioscience

NASDAQ:TWST

TWST Rankings

TWST Latest News

TWST Latest SEC Filings

TWST Stock Data

1.67B
59.18M
1.88%
116.74%
17.29%
Diagnostics & Research
Biological Products, (no Disgnostic Substances)
Link
United States
SOUTH SAN FRANCISCO